Cretostimogene lowers bladder cancer recurrence in phase 3 trial, company says; AUA amends ejaculation guideline; kidney cancer IO benefit tracks risk

Listen to this post
read by AI voices · all episodesCG Oncology said its phase 3 PIVOT-006 trial found cretostimogene improved recurrence-free survival versus surveillance in intermediate-risk and high-grade Ta non-muscle invasive bladder cancer, in topline results. The American Urological Association (AUA) amended its ejaculation disorders guideline, a meta-analysis found first-line checkpoint inhibitor combinations helped most in poor-risk kidney cancer, and a phase 2 trial tested kidney-sparing treatment for upper tract urothelial carcinoma.
- Research Nov 16, 2026CG Oncology said Nov. 16 that PIVOT-006, a randomized phase 3 trial of 367 patients with intermediate-risk or high-grade Ta non-muscle invasive bladder cancer, showed cretostimogene after complete tumor resection improved recurrence-free survival versus surveillance (hazard ratio 0.32, 95% CI 0.23 to 0.45; P < .0001) at 17 months' median follow-up. The topline results, not yet peer reviewed, showed no grade 3 or higher treatment-related adverse events, the company said. Full data are to be presented at the Society of Urologic Oncology meeting Dec. 2, and the company said they will support a second biologics license application in 2027.
- Guidelines Nov 17, 2026The American Urological Association (AUA) released an amendment to the Disorders of Ejaculation: AUA/SMSNA Guideline, summarized Nov. 17 in The Journal of Urology and informed by 25 studies. It adds an expert opinion statement on PDE5 inhibitors for premature ejaculation and two statements on daily or on-demand clomipramine and glans hyaluronic acid injection, which the panel said should be used with informed consent and at the behest of a trained clinician. A statement on non-pharmacological therapies was revised to reflect evidence that some may be effective.
- Research Nov 16, 2026A meta-analysis of the CheckMate-214, CheckMate-9ER, KEYNOTE-426 and CLEAR trials, with 3,320 patients with metastatic clear cell renal cell carcinoma, published Nov. 16 in European Urology, found pooled overall survival hazard ratios versus sunitinib of 0.98 (95% CI 0.81 to 1.19) in International Metastatic Renal Cell Carcinoma Database Consortium favorable-risk, 0.78 (0.68 to 0.89) in intermediate-risk and 0.51 (0.40 to 0.65) in poor-risk disease. Programmed death-ligand 1 expression at 5% significantly modified the treatment effect. The authors said benefit was strongest in patients with a poor prognosis.Sources: European Urology, PubMed
- Research Nov 20, 2026In a single-arm phase 2 trial at two centers in China, published Nov. 20 in The Lancet Oncology, 20 patients with localized high-risk upper tract urothelial carcinoma received disitamab vedotin plus tislelizumab for two to four cycles, followed by response-adapted kidney-sparing surgery when feasible. The 1-year kidney-intact event-free survival rate, the primary end point, was 70% (95% CI 46 to 88). Grade 3 treatment-related adverse events occurred in two patients (10%), with no grade 4 or 5 events, and the authors called for comparative trials.Sources: The Lancet Oncology, PubMed
The weekly innovation roundup for urology, published every Sunday for the week before; every item links to its sources. Latest urology news · All specialties